2017 Annual Report

“We have grown into a fully-fledged research infrastructure, playing a pivotal role both nationally and internationally”

Catherine Larue

Chief Executive Officer

MORE

A MOVE FOR THE BETTER

In November 2017, IBBL relocated its entire staff and operations from Luxembourg City to a permanent location in Dudelange. The precision and rigour of the underlying management ensured a seamless transition. The newly built facilities, in the Laboratoire National de Santé (LNS) building Phase 2, boast a 2,000 m2 floor area and a storage capacity of about 5 million samples. The bespoke building is already allowing IBBL to expand its operations and service offering.

MORE

BIOSPECIMEN PROFICIENCY TESTING

COLLECTION
STATISTICS


 

A PIONEER IN QUALITY AND STANDARDISATION

2017 was marked by four important steps with regard to quality. Internationally, the ISO/DIS 20387 biobanking standard draft was approved and the draft ISO/AWI 21899 norm published. Internally, IBBL successfully passed the recertification audit for ISO 9001:2008 and started preparing to become an authorised GMP storage infrastructure.

MORE

DIAGNOSING SAMPLE ‘HEALTH’

In 2017, IBBL’s Biorefinery Department took yet another step forward in advancing biospecimen research. The team published the results of a study that identified and validated two cytokine biomarkers to be used as an assay to evaluate the quality and fitness for purpose of serum and plasma samples. This discovery bears important implications for the accuracy and reliability of downstream biomedical research.

MORE

FINANCES


STAFF


COLORECTAL CANCER: A NATIONAL PRIORITY

IBBL works in close collaboration with national players to support research across a variety of areas, from Parkinson’s Disease (under the National Centre for Excellence in Research in Parkinson’s Disease) to personalised medicine (through the Personalised Medicine Consortium of Luxembourg) and cancer (under the National Cancer Plan). An instance of successful cooperation is the SOCS (Suppressor Of Cytokine Signaling) project which saw the discovery of the protein MYO5B as a colorectal cancer biomarker in 2017.

MORE

THE EXTERNAL QUALITY ASSESSMENT (EQA) PROGRAMME PROVIDER TO EU CONSORTIA

Aside from supplying traditional biobanking services to EU consortia, IBBL has increasingly been strengthening its position as the EU provider of external quality assessment (EQA) schemes through its participation in several EU-funded projects. In 2017, another opportunity to share its expertise in this area saw its official kick off – the project SPIDIA4P (Standardisation of generic Preanalytical Procedures for In vitro DIAgnostics for Personalised Medicine), aiming to promote the standardisation of biobanking operations.

MORE

OUR CLIENTS & PARTNERS


MORE

OUR PUBLICATIONS


MORE

OUR PROJECTS


MORE

DOWNLOAD ANNUAL REPORT


OLD EDITIONS